Immunosuppression with cyclophosphamide favors reinfection with recombinant Toxoplasma gondii strains.
The aim of this study was to verify the effect of immunosuppression by cyclophosphamide (Cy) on susceptibility of BALB/c mice subjected to challenge with recombinant strains of Toxoplasma gondii. Animals were prime infected with the D8 (recombinant I/III) or the ME49 (type II) non-virulent strains, weekly immunosuppressed with Cy and challenged with the CH3 or EGS virulent strains (I/III). Parasites recovered from surviving mice were submitted to PCR-RFLP analysis to confirm co-infection. Prime-infection with the D8 strain conferred more protection against challenge with the CH3 and EGS strains when compared with ME49 prime infection. Cy treatment caused significant leukopenia in the infected mice, what probably favors reinfection after challenge. Reinfection was associated with increased levels of IgA. Otherwise, Cy-treated mice presented significantly lower IgA levels after challenge, suggesting involvement of this immunoglobulin on protection against reinfection. In conclusion, BALB/c mice susceptibility to reinfection by T. gondii is related to genetic differences among the strains used for primary and challenge infections. Alteration of the host's immune integrity by Cy probably compromises the protection previously established by primary infection.
Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (UFMG), Av. Antonio Carlos 6627, 31270-901, Belo Horizonte, MG, Brazil.
L A
LA
Silva
G P
GP
Brandão
B V
BV
Pinheiro
R W A
RW
Vitor
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D001921:Brain / Q000469:parasitology; D002645:Chickens; D003520:Cyclophosphamide / Q000494:pharmacology / Q000627:therapeutic use*; D016054:DNA, Protozoan / Q000737:chemistry; D004195:Disease Models, Animal; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007136:Immunoglobulins / Q000097:blood; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007958:Leukocyte Count; D051379:Mice; D008807:Mice, Inbred BALB C; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D014122:Toxoplasma / Q000187:drug effects* / Q000235:genetics / Q000276:immunology; D014124:Toxoplasmosis, Animal / Q000188:drug therapy / Q000276:immunology*; D014125:Toxoplasmosis, Congenital / Q000469:parasitology
D000913:Antibodies, Protozoan; D016054:DNA, Protozoan; D007136:Immunoglobulins; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide